Poland· PL-100431671
Kastel
A rosuvastatin und ramipril product containing rosuvastatinum + ramiprilum, registered in Poland by Egis Pharmaceuticals PLC. The same ATC class is registered in 2 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Rosuvastatin und ramipril is registered in 2 of 19 countries.
Countries holding a registration under ATC C10BX17 (rosuvastatin und ramipril), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Rosuvastatin und ramipril · ATC C10BX17
2 / 19 countries
- Czechiaprice
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Rosuvastatinum + Ramiprilum
- Manufacturer
- Egis Pharmaceuticals PLC
- Country
- Poland (PL)
- ATC code
- C10BX17
- ATC class
- Rosuvastatin und Ramipril
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 7
- gtin05995327176901
- gtin05995327188348
- gtin05995327194516
- gtin05995327194523
- gtin05995327194530
- gtin05995327188362
- gtin05995327188355
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rosuvastatin und ramipril in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKASTELEgis Pharmaceuticals PLC, Budapešť
- SpainROSUVASTATINA/RAMIPRIL EGIS 10 MG/10 MG CÁPSULAS DURASEgis Pharmaceuticals Plc.
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- Czechia · Kastel
- Spain · Rosuvastatina/Ramipril Egis
- Greece · Rosuvastatin+ramipril Egis, Rosuvastatin+ramipril/Egis
- Hungary · Romus, Rosuvastatin/Ramipril Egis
- Italy · Asurami, Rosuvastatina E Ramipril Egis
- Lithuania · Ramostin
- Latvia · Ramostin
- Portugal · Rosuvastatina + Ramipril Egis, Rosuvastatina + Ramipril Sandoz
- Slovakia · Rosuramlon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c3daf314-5610-4709-84f7-3671cc2854d5 GET /v1/drugs/c3daf314-5610-4709-84f7-3671cc2854d5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "20 mg + 10 mg",
"packaging": "05995327176901 ¦ Rp ¦ 142767\n30 kaps.\n05995327188348 ¦ Rp ¦ Skasowane ¦ 142768\n60 kaps.\n05995327188362 ¦ Rp ¦ Skasowane ¦ 142769\n100 kaps.\n05995327188355 ¦ Rp ¦ Skasowane ¦ 142770\n90 kaps.\n05995327194516 ¦ Rp ¦ 152200\n60 kaps.\n05995327194523 ¦ Rp ¦ 152201\n90 kaps.\n05995327194530 ¦ Rp ¦ 152202\n100 kaps.",
"substance": "Rosuvastatinum w postaci Rosuvastatinum calicum 20,84 mg + Ramiprilum 10 mg",
"common_name": "Rosuvastatinum + Ramiprilum",
"pl_product_id": "100431671",
"pozwolenie_nr": "26774",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about rosuvastatin und ramipril.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.